Login
Companies $AARD
$1.21 -$0.05 (4.22%) After hours
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc.

aardvarktherapeutics.com

What Do They Do?

Develops small-molecule medicines that activate gut bitter-taste receptors to address hunger-related conditions, including Prader-Willi syndrome and other metabolic diseases.

How Are They Changing?

Since the FY2025 annual report
  • Nov 13, 2026 FDA lifted the clinical hold on ARD-101 Aardvark may conduct an open-label trial at 200 mg twice daily and expects to resume PWS clinical activities in 2027, subject to FDA alignment.

Who Do They Compete With?

Competes with Soleno Therapeutics, Rhythm Pharmaceuticals, Relmada Therapeutics, and Bright Minds Biosciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support